中信股份(00267)與中信集團續展新財務資助框架協議
格隆匯11月20日丨中信股份(00267)發佈公告,2016年11月30日,公司與中信集團簽訂2016財務資助框架協議,有效期限自2017年1月1日至2019年12月31日。2016財務資助框架協議將於2019年12月31日到期。考慮到集團與中信集團的業務發展需要,2019年11月20日,公司與中信集團續展新財務資助框架協議,其中載列集團成員公司將向中信集團及/或其聯繫人提供財務資助的基準及年度上限。該新財務資助框架協議下交易的具體協議將會在集團成員與中信集團及/或其聯繫人之間達成。該等具體協議將於所有重大方面遵循新財務資助框架協議中規定的準則和條款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.